Home / AVCNF : OTC

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does AVCNF make money? Does AVCNF have pricing power? What's the Earnings Whisper? Will AVCNF profit more as the business scales? What is AVCNF's management track record? Is AVCNF's current price justified?

Avicanna Inc.

$0.09 -$0.08 (-46.91%)

OTC · 11 Sep 2026 20:00 UTC

Previous Close

$0.08

Day Range

$0.08$0.09

Year Range

$0.07$0.22

Market Cap

10.82M

AVG Volume

95.27K

Trailing/Forward PE

-3.4/-

PEG ratio

0.05

Dividend Yield

Next Earnings Date

2026-11-13

Primary Exchange

Other OTC

Revenue (CAD)

AVCNF Revenue (CAD) by year
Period	Revenue (CAD)
2025	25.47M
2024	25.46M
2023	16.79M
2022	4.05M
2021	3.27M
2020	1.57M
2019	168.25K
2018	117.97K

Net Income (CAD)

AVCNF Net Income (CAD) by year
Period	Net Income (CAD)
2025	-2.93M
2024	-3.39M
2023	-8.27M
2022	-14.74M
2021	-16.77M
2020	-32.86M
2019	-21.07M
2018	-7M

Operating Income (CAD)

AVCNF Operating Income (CAD) by year
Period	Operating Income (CAD)
2025	-2.76M
2024	-4.23M
2023	-7.47M
2022	-10.58M
2021	-10.83M
2020	-18.44M
2019	-22.65M
2018	-10.25M

EBITDA (CAD)

AVCNF EBITDA (CAD) by year
Period	EBITDA (CAD)
2025	-2.01M
2024	-2.42M
2023	-7.36M
2022	-11.26M
2021	-10.05M
2020	-20.34M
2019	-21.54M
2018	-8.98M

Cash Flows (CAD)

AVCNF Cash Flows (CAD) by year
Period	Cash Flows (CAD)
2025	-1.44M
2024	-2.95M
2023	-1.96M
2022	-7.5M
2021	-12.43M
2020	-15.43M
2019	-26.94M
2018	-11.33M

EPS (CAD)

AVCNF EPS (CAD) by year
Period	EPS (CAD)
2025	-0.03
2024	-0.04
2023	-0.1
2022	-0.24
2021	-0.4
2020	-1.11
2019	-1.01
2018	-0.46

Expenses (CAD)

AVCNF Expenses (CAD) by year
Period	Expenses (CAD)
2025	15.63M
2024	16.65M
2023	14.39M
2022	10.33M
2021	13.95M
2020	18.07M
2019	30M
2018	14.57M

Cash & Debt (CAD)

AVCNF Cash & Debt (CAD) by year
Period	Cash & Debt (CAD)
2025	280.4K
2024	448.03K
2023	477.2K
2022	1.19M
2021	31K
2020	2.52M
2019	441.76K
2018	69.3K

Debt ratios

AVCNF Debt ratios by year
Period	Debt ratios
2025	0.01
2024	0.01
2023	-0.03
2022	-0.03
2021	-0.03

Margins

AVCNF Margins by year
Period	Margins
2025	52.49%
2024	50.88%
2023	41.97%
2022	-10.12%
2021	49.74%
2020	-263.9%
2019	-563.8%
2018	100%

Return on Capital

AVCNF Return on Capital by year
Period	Return on Capital
2025	-25.79%
2024	-34.79%
2023	-103.72%
2022	-426.04%
2021	-242.83%
2020	-236.25%
2019	-70.53%
2018	-26.52%

Shares Outstanding

AVCNF Shares Outstanding by year
Period	Shares Outstanding
2025	118.62M
2024	100.03M
2023	90.68M
2022	74.95M
2021	45.73M
2020	35.87M
2019	24.12M
2018	14.83M

Book Value Per Share (CAD)

AVCNF Book Value Per Share (CAD) by year
Period	Book Value Per Share (CAD)
2025	0.1
2024	0.1
2023	0.09
2022	0.05
2021	0.15
2020	0.39
2019	1.24
2018	1.78

Total Assets (CAD)

AVCNF Total Assets (CAD) by year
Period	Total Assets (CAD)
2025	21.23M
2024	20.12M
2023	21.97M
2022	17.62M
2021	22.3M
2020	30.16M
2019	45.16M
2018	28.18M

Free Cash Flow Yield

AVCNF Free Cash Flow Yield by year
Period	Free Cash Flow Yield
Sep 26	-15.85%
Sep 26	-14.46%
Aug 26	-15.12%
Aug 26	-14.1%
Aug 26	-14.21%
Aug 26	-14.65%
Jul 26	-14.55%
Jul 26	-13.47%
Jul 26	-14.07%
Jul 26	-13.92%
Jul 26	-14.99%
Jun 26	-10.04%
Jun 26	-9.3%
Jun 26	-10.09%
Jun 26	-10.48%
May 26	-9.66%
May 26	-8.94%
May 26	-9.14%
May 26	-8.95%
May 26	-8.11%
Apr 26	-8.28%
Apr 26	-8.04%
Apr 26	-7.5%
Apr 26	-8.28%
Mar 26	-10.02%
Mar 26	-9.13%
Mar 26	-8.67%
Mar 26	-8.41%
Feb 26	-8.27%
Feb 26	-9.19%
Feb 26	-8.59%
Feb 26	-8.44%
Jan 26	-7.65%
Jan 26	-6.89%
Jan 26	-7.18%
Jan 26	-6.6%
Jan 26	-7.01%
Dec 25	-4.7%
Dec 25	-4.58%
Dec 25	-4.72%
Dec 25	-4.71%
Nov 25	-4.6%
Nov 25	-4.48%
Nov 25	-4.35%
Nov 25	-4.23%
Oct 25	-3.99%
Oct 25	-3.99%
Oct 25	-3.98%
Oct 25	-3.98%
Oct 25	-4.14%
Sep 25	-11.46%
Sep 25	-11.25%
Sep 25	-10.46%
Sep 25	-10.51%
Aug 25	-10.47%
Aug 25	-10.3%
Aug 25	-10.81%
Aug 25	-10.53%
Aug 25	-10.4%
Jul 25	-9.57%
Jul 25	-11.07%
Jul 25	-11.81%
Jul 25	-10.67%
Jun 25	-10.88%
Jun 25	-11.3%
Jun 25	-12.3%
Jun 25	-12.9%
May 25	-10.9%
May 25	-10.03%
May 25	-10.27%
May 25	-11.76%
May 25	-12.14%
Apr 25	-12.44%
Apr 25	-12.26%
Apr 25	-13.37%
Apr 25	-12.88%
Mar 25	-10.74%
Mar 25	-9.41%
Mar 25	-9.3%
Mar 25	-9.12%
Feb 25	-10.59%
Feb 25	-11.92%
Feb 25	-13.12%
Feb 25	-11.99%
Jan 25	-12.52%
Jan 25	-10.61%
Jan 25	-10.87%
Jan 25	-13.68%
Jan 25	-10.4%
Dec 24	-2.18%
Dec 24	-1.97%
Dec 24	-1.65%
Dec 24	-2.24%
Nov 24	-1.82%
Nov 24	-2.45%
Nov 24	-2.69%
Nov 24	-2.29%
Nov 24	-2.09%
Oct 24	-2.22%
Oct 24	-2.17%

Price to Sales

AVCNF Price to Sales by year
Period	Price to Sales
Sep 26	0.55
Sep 26	0.6
Aug 26	0.58
Aug 26	0.62
Aug 26	0.61
Aug 26	0.59
Jul 26	0.6
Jul 26	0.65
Jul 26	0.62
Jul 26	0.63
Jul 26	0.58
Jun 26	0.56
Jun 26	0.61
Jun 26	0.56
Jun 26	0.54
May 26	0.58
May 26	0.63
May 26	0.62
May 26	0.63
May 26	0.7
Apr 26	0.68
Apr 26	0.7
Apr 26	0.75
Apr 26	0.68
Mar 26	0.7
Mar 26	0.77
Mar 26	0.81
Mar 26	0.83
Feb 26	0.85
Feb 26	0.76
Feb 26	0.82
Feb 26	0.83
Jan 26	0.92
Jan 26	1.02
Jan 26	0.98
Jan 26	1.06
Jan 26	1
Dec 25	1
Dec 25	1.02
Dec 25	0.99
Dec 25	1
Nov 25	1.02
Nov 25	1.05
Nov 25	1.08
Nov 25	1.11
Oct 25	1.18
Oct 25	1.17
Oct 25	1.18
Oct 25	1.18
Oct 25	1.13
Sep 25	1.1
Sep 25	1.12
Sep 25	1.2
Sep 25	1.19
Aug 25	1.2
Aug 25	1.22
Aug 25	1.16
Aug 25	1.19
Aug 25	1.21
Jul 25	1.31
Jul 25	1.13
Jul 25	1.06
Jul 25	1.18
Jun 25	1.07
Jun 25	1.03
Jun 25	0.94
Jun 25	0.9
May 25	1.06
May 25	1.15
May 25	1.13
May 25	0.99
May 25	0.95
Apr 25	0.93
Apr 25	0.95
Apr 25	0.87
Apr 25	0.9
Mar 25	1.23
Mar 25	1.41
Mar 25	1.43
Mar 25	1.45
Feb 25	1.25
Feb 25	1.11
Feb 25	1.01
Feb 25	1.11
Jan 25	1.06
Jan 25	1.25
Jan 25	1.22
Jan 25	0.97
Jan 25	1.28
Dec 24	1.1
Dec 24	1.22
Dec 24	1.45
Dec 24	1.07
Nov 24	1.32
Nov 24	0.98
Nov 24	0.89
Nov 24	1.05
Nov 24	1.15
Oct 24	1.08
Oct 24	1.11

Price/Operating Cashflow

AVCNF Price/Operating Cashflow by year
Period	Price/Operating Cashflow
Sep 24	38.25
Sep 24	48.8
Sep 24	42.76
Sep 24	45.3
Aug 24	46.92
Aug 24	38.54
Aug 24	39.91
Aug 24	34.16
Aug 24	34.85
Jul 24	37.2
Jul 24	44.04
Jul 24	57.04
Jul 24	40.33

Price to Book

AVCNF Price to Book by year
Period	Price to Book
Sep 26	1.11
Sep 26	1.21
Aug 26	1.16
Aug 26	1.24
Aug 26	1.24
Aug 26	1.2
Jul 26	1.21
Jul 26	1.3
Jul 26	1.25
Jul 26	1.26
Jul 26	1.17
Jun 26	1.26
Jun 26	1.36
Jun 26	1.25
Jun 26	1.2
May 26	1.31
May 26	1.41
May 26	1.38
May 26	1.41
May 26	1.56
Apr 26	1.52
Apr 26	1.57
Apr 26	1.68
Apr 26	1.53
Mar 26	1.52
Mar 26	1.67
Mar 26	1.76
Mar 26	1.82
Feb 26	1.85
Feb 26	1.66
Feb 26	1.78
Feb 26	1.81
Jan 26	1.99
Jan 26	2.21
Jan 26	2.13
Jan 26	2.31
Jan 26	2.18
Dec 25	2.33
Dec 25	2.39
Dec 25	2.32
Dec 25	2.33
Nov 25	2.38
Nov 25	2.45
Nov 25	2.52
Nov 25	2.59
Oct 25	2.75
Oct 25	2.75
Oct 25	2.76
Oct 25	2.75
Oct 25	2.65
Sep 25	2.57
Sep 25	2.61
Sep 25	2.81
Sep 25	2.8
Aug 25	2.81
Aug 25	2.85
Aug 25	2.72
Aug 25	2.79
Aug 25	2.83
Jul 25	3.07
Jul 25	2.65
Jul 25	2.49
Jul 25	2.76
Jun 25	2.78
Jun 25	2.68
Jun 25	2.46
Jun 25	2.35
May 25	2.78
May 25	3.02
May 25	2.95
May 25	2.57
May 25	2.49
Apr 25	2.43
Apr 25	2.47
Apr 25	2.26
Apr 25	2.35
Mar 25	3.34
Mar 25	3.82
Mar 25	3.86
Mar 25	3.94
Feb 25	3.39
Feb 25	3.01
Feb 25	2.74
Feb 25	2.99
Jan 25	2.87
Jan 25	3.39
Jan 25	3.3
Jan 25	2.63
Jan 25	3.45
Dec 24	3.44
Dec 24	3.81
Dec 24	4.54
Dec 24	3.35
Nov 24	4.12
Nov 24	3.06
Nov 24	2.79
Nov 24	3.27
Nov 24	3.6
Oct 24	3.39
Oct 24	3.46

No video analysis for this stock yet. Request one from our team.

News: AVCNF

globenewswire.com · 9 Sep 2026

Avicanna Launches MyMedi.ca Integrated Healthcare Program in Canada

Integrating MyMedi.ca healthcare provider-guided medical cannabis care into hospitals, specialty clinics, insurers and multidisciplinary healthcare networks in Canada Integrating MyMedi.ca healthcare provider-guided medical cannabis care into hospitals, specialty clinics, insurers and multidisciplinary healthcare networks in Canada

globenewswire.com · 19 Aug 2026

Avicanna Announces Closing of Strategic Non-Brokered Private Placement

Strategic investment by pharmaceutical executive and life sciences investor Michael Porter Strategic investment by pharmaceutical executive and life sciences investor Michael Porter

globenewswire.com · 14 Aug 2026

Avicanna Reports Q2 2026 Financial Results

Gross margin improves to 57%, supported by 48% quarterly growth in proprietary product sales QUIX™ rapid-onset portfolio prepared for Q3 launch with more than 35 commercial listings secured

globenewswire.com · 16 Jul 2026

Avicanna Introduces QUIX™ Rapid-Onset Medical Cannabis Portfolio

Initial Medical Cannabis SKUs, Including Rapid-Onset Capsules and Soft Chews, Planned for Q3 2026 Improving Patient Access with Accurately Dosed, Rapid-Onset and Non-Combustible Formats

globenewswire.com · 30 Jun 2026

Avicanna Announces Promotion of Nick Hilborn CPA CA to Chief Financial Officer

TORONTO, June 30, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce Mr. Nick Hilborn, CPA, CA has been promoted to the position of Chief Financial Officer (CFO) effective immediately. Mr. Hilborn served as the Interim CFO at the Company since September 2025, and previously held the role of Vice President of Finance since July 2024. Prior to joining the Company, Mr. Hilborn held roles at Telus, EY, and PwC.

globenewswire.com · 15 Jun 2026

Splash Beverage Group Invests in Avicanna, a Leading Cannabinoid Biopharmaceutical Platform, Advancing Its Transformation Into Cannabinoid Healthcare

FORT LAUDERDALE, Fla., June 15, 2026 (GLOBE NEWSWIRE) -- Splash Beverage Group, Inc. (NYSE American: SBEV) today announced the completion of a CDN$300,000 strategic investment in Avicanna Inc. (TSX: AVCN), a commercial-stage cannabinoid-based biopharmaceutical company focused on clinical research, patient care, and developing pharmaceutical products.